Investigation of DNA-damage and chromosomal aberrations in blood cells under the influence of new silver-based antiviral complex

Evgenii Plotnikov, Vladimir Silnikov, Andrew Gapeyev, Vladimir Plotnikov

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: The problem of infectious diseases and drug resistance is becoming increasingly important worldwide. Silver is extensively used as an anti-infective agent, but it has significant toxic side effects. In this regard, it is topical to develop new silver compounds with high biological activity and low toxicity. This work is aimed to study DNA damage and chromosomal aberrations in blood cells under the influence of new silver-based compound of general formula C6H19Ag2N4LiO6S2, with antiviral activity. Methods: The comet assay was applied for the genotoxic affects assessment on mice blood leukocytes. DNA damage was determined bases on the percentage of DNA in a comet tail (tail DNA), under the influence of silver complex in different concentrations. Genotoxic effect of the tested substance on the somatic cells was determined by chromosomal aberration test of bone marrow cells of mice. Results: In the course of the experiments, no essential changes in the level of DNA damage in the cells were found, even at highest concentrations. The administration of the substance in doses up to 2.5 g/kg in mice did not cause any increase in the frequency of chromosomal aberration in bone marrow cells. Conclusion: Taking into account known silver drug genotoxic properties, the use of a given complexed silver compound has possible great advantages for potential applications in the treatment of infectious diseases.

Original languageEnglish
Pages (from-to)71-74
Number of pages4
JournalAdvanced Pharmaceutical Bulletin
Volume6
Issue number1
DOIs
Publication statusPublished - 1 Mar 2016

Fingerprint

Silver Compounds
Silver
Chromosome Aberrations
DNA Damage
Antiviral Agents
Blood Cells
Bone Marrow Cells
Communicable Diseases
Tail
Disease Resistance
Comet Assay
Poisons
DNA
Anti-Infective Agents
Drug Resistance
Leukocytes
Pharmaceutical Preparations

Keywords

  • Antiviral compound
  • Chromosomal aberrations
  • Comet assay
  • Genotoxicity
  • Silver complex

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Investigation of DNA-damage and chromosomal aberrations in blood cells under the influence of new silver-based antiviral complex. / Plotnikov, Evgenii; Silnikov, Vladimir; Gapeyev, Andrew; Plotnikov, Vladimir.

In: Advanced Pharmaceutical Bulletin, Vol. 6, No. 1, 01.03.2016, p. 71-74.

Research output: Contribution to journalArticle

@article{8b27daec00404d80b038dd69bb4d025b,
title = "Investigation of DNA-damage and chromosomal aberrations in blood cells under the influence of new silver-based antiviral complex",
abstract = "Purpose: The problem of infectious diseases and drug resistance is becoming increasingly important worldwide. Silver is extensively used as an anti-infective agent, but it has significant toxic side effects. In this regard, it is topical to develop new silver compounds with high biological activity and low toxicity. This work is aimed to study DNA damage and chromosomal aberrations in blood cells under the influence of new silver-based compound of general formula C6H19Ag2N4LiO6S2, with antiviral activity. Methods: The comet assay was applied for the genotoxic affects assessment on mice blood leukocytes. DNA damage was determined bases on the percentage of DNA in a comet tail (tail DNA), under the influence of silver complex in different concentrations. Genotoxic effect of the tested substance on the somatic cells was determined by chromosomal aberration test of bone marrow cells of mice. Results: In the course of the experiments, no essential changes in the level of DNA damage in the cells were found, even at highest concentrations. The administration of the substance in doses up to 2.5 g/kg in mice did not cause any increase in the frequency of chromosomal aberration in bone marrow cells. Conclusion: Taking into account known silver drug genotoxic properties, the use of a given complexed silver compound has possible great advantages for potential applications in the treatment of infectious diseases.",
keywords = "Antiviral compound, Chromosomal aberrations, Comet assay, Genotoxicity, Silver complex",
author = "Evgenii Plotnikov and Vladimir Silnikov and Andrew Gapeyev and Vladimir Plotnikov",
year = "2016",
month = "3",
day = "1",
doi = "10.15171/apb.2016.011",
language = "English",
volume = "6",
pages = "71--74",
journal = "Advanced Pharmaceutical Bulletin",
issn = "2228-5881",
publisher = "Tabriz University of Medical Sciences, Faculty of Pharmacy",
number = "1",

}

TY - JOUR

T1 - Investigation of DNA-damage and chromosomal aberrations in blood cells under the influence of new silver-based antiviral complex

AU - Plotnikov, Evgenii

AU - Silnikov, Vladimir

AU - Gapeyev, Andrew

AU - Plotnikov, Vladimir

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose: The problem of infectious diseases and drug resistance is becoming increasingly important worldwide. Silver is extensively used as an anti-infective agent, but it has significant toxic side effects. In this regard, it is topical to develop new silver compounds with high biological activity and low toxicity. This work is aimed to study DNA damage and chromosomal aberrations in blood cells under the influence of new silver-based compound of general formula C6H19Ag2N4LiO6S2, with antiviral activity. Methods: The comet assay was applied for the genotoxic affects assessment on mice blood leukocytes. DNA damage was determined bases on the percentage of DNA in a comet tail (tail DNA), under the influence of silver complex in different concentrations. Genotoxic effect of the tested substance on the somatic cells was determined by chromosomal aberration test of bone marrow cells of mice. Results: In the course of the experiments, no essential changes in the level of DNA damage in the cells were found, even at highest concentrations. The administration of the substance in doses up to 2.5 g/kg in mice did not cause any increase in the frequency of chromosomal aberration in bone marrow cells. Conclusion: Taking into account known silver drug genotoxic properties, the use of a given complexed silver compound has possible great advantages for potential applications in the treatment of infectious diseases.

AB - Purpose: The problem of infectious diseases and drug resistance is becoming increasingly important worldwide. Silver is extensively used as an anti-infective agent, but it has significant toxic side effects. In this regard, it is topical to develop new silver compounds with high biological activity and low toxicity. This work is aimed to study DNA damage and chromosomal aberrations in blood cells under the influence of new silver-based compound of general formula C6H19Ag2N4LiO6S2, with antiviral activity. Methods: The comet assay was applied for the genotoxic affects assessment on mice blood leukocytes. DNA damage was determined bases on the percentage of DNA in a comet tail (tail DNA), under the influence of silver complex in different concentrations. Genotoxic effect of the tested substance on the somatic cells was determined by chromosomal aberration test of bone marrow cells of mice. Results: In the course of the experiments, no essential changes in the level of DNA damage in the cells were found, even at highest concentrations. The administration of the substance in doses up to 2.5 g/kg in mice did not cause any increase in the frequency of chromosomal aberration in bone marrow cells. Conclusion: Taking into account known silver drug genotoxic properties, the use of a given complexed silver compound has possible great advantages for potential applications in the treatment of infectious diseases.

KW - Antiviral compound

KW - Chromosomal aberrations

KW - Comet assay

KW - Genotoxicity

KW - Silver complex

UR - http://www.scopus.com/inward/record.url?scp=84962339516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962339516&partnerID=8YFLogxK

U2 - 10.15171/apb.2016.011

DO - 10.15171/apb.2016.011

M3 - Article

VL - 6

SP - 71

EP - 74

JO - Advanced Pharmaceutical Bulletin

JF - Advanced Pharmaceutical Bulletin

SN - 2228-5881

IS - 1

ER -